CClinicalTrials.gg
Not yet recruitingNCT06640699Updated Oct 15, 2024

The Effects of Neurophysiological Facilitation Techniques After Coronary Artery Bypass Graft Surgery

An interventional study of exercise in Cardiac Disease, sponsored by Istanbul University - Cerrahpasa. Not yet recruiting. Open to participants aged 50 Years to 85 Years. Per ClinicalTrials.gov, last updated 2024-10-15.

Sponsored by Istanbul University - Cerrahpasa · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Feb 2025, 1 year 8 months ago, but the record still lists the study as not yet recruiting.
Phase
Not applicable
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
50 Years to 85 Years
Sex
All
01

Study summary

The aim of the study is to investigate the effects of neurophysiological facilitation techniques, applied in addition to Phase I cardiac rehabilitation in the early postoperative period after coronary artery bypass graft (CABG) surgery, on left ventricular function, respiratory functions, and functional capacity.

Read the detailed description

In this prospective randomized controlled study, participants will be randomly divided into two groups: the control group, which will receive Phase I cardiac rehabilitation, and the treatment group, which will receive Phase I cardiac rehabilitation along with the application of neurophysiological facilitation techniques. The participants' left ventricular function, respiratory functions, and functional capacity will be assessed before and after the interventions.

02

Conditions studied

  • Cardiac Disease

Browse trials for

Keywords

  • coronary artery bypass
  • respiratory function test
  • ventricular ejection fraction
03

In context

Heart Diseases

3,639 studies on the registry are indexed under Heart Diseases; 461 are open to participants now.

This study's planned enrollment of 36 is below the median of 100 across 1,778 interventional studies indexed under Heart Diseases.

Browse Heart Diseases studies →

Lead sponsor

Istanbul University - Cerrahpasa is the lead sponsor of 680 studies on the registry; 208 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • First-time undergoing open-heart surgery
  • Aged between 50 and 85 years
  • Full cooperation

Exclusion criteria

Exclusion Criteria:

  • Presence of facial, sternum, or rib fractures
  • Chronic renal failure
  • Development of cerebrovascular events
  • Cognitive function impairment
  • Development of deep vein thrombosis in the postoperative period
  • Presence of neuromuscular disease
  • Presence of orthopedic disabilities
  • Intubation duration longer than 24 hours
  • Staying in intensive care for more than 48 hours
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
36 participants (estimated)

Study arms

  • Experimental
    NFT Group

    NFT group will receive Phase I cardiac rehabilitation and neurophysiological facilitation techniques.

    Other: exercise

  • Active comparator
    Control Group

    Control group will receive Phase I cardiac rehabilitation alone.

    Other: exercise

Interventions

  • Otherexercise

    exercises with using neurophysiological facilitation techniques and cardiac rehabilitation.

06

What researchers measure

Primary outcomes

  1. ecocardiography device

    ejection fraction will assess with ecocardiography.

    Time frame: 3 months

  2. spirometer

    respiratory function test will assess with spirometer

    Time frame: 3 months

  3. 6 Minutes walking test

    functional capacity will assess with 6 minutes walk test.

    Time frame: 3 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 15, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06640699
Lead sponsor
Istanbul University - Cerrahpasa
Collaborators
Okan University
Responsible party
Gamze Aydin (Principal Investigator, Istanbul University - Cerrahpasa) — Principal investigator
First posted
Oct 15, 2024
Start date
Nov 1, 2024 (estimated)
Primary completion
Feb 1, 2025 (estimated)
Completion
Mar 1, 2025 (estimated)
Last update
Oct 15, 2024

Study contacts

Gamze Aydın, PhD
Contact
gamze.tosun@okan.edu.tr
05377600256
Gamze Aydın, PhD
principal investigator · Okan University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion